EUROIMMUN releases new quantitative anti-SARS-CoV-2 ELISA
The new Anti-SARS-CoV-2 QuantiVac ELISA (IgG) from EUROIMMUN provides quantitative detection of IgG antibodies against the viral S1 antigen, including the receptor binding domain. The ELISA is one of the first commercial antibody tests to allow quantification of the antibody concentration in standardised units (BAU/ml) based on the first WHO International Standard for anti-SARS-CoV-2 immunoglobulin (NIBSC code: 20/136).
The assay uses a 6-point calibration curve, ensuring a broad linear range. Quantitative antibody measurement can be a valuable support in the assessment of individual immune responses to SARS-CoV-2 after infection. It also plays an important role in vaccine development and application, supporting evaluation of the level of immune protection conferred by spike protein-based vaccines.
The assay is validated for serum, plasma and dried capillary blood as sample material and is fully automatable. The anti-SARS-CoV-2 QuantiVac ELISA (IgG) complements EUROIMMUN’s extensive portfolio of COVID-19 diagnostic tests, which encompasses RT-PCR assays, an antigen ELISA, semi-quantitative ELISAs based on S1 (IgG, IgA) or modified nucleocapsid protein (IgG, IgM) and a CE-marked set for convenient collection of capillary blood for IgG analysis.
For more information, visit: www.coronavirus-diagnostics.com
